FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:957-959 March 5, 2009 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

In a recent article, Yadav et al.¹ elucidated the regulation of gut-produced serotonin by low-density lipoprotein receptor–related protein 5 (Lrp5) and the deleterious effect of serotonin on bone mass. This discovery reflects the rapid advances taking place in bone biology and lends support to three newly understood facts about skeletal physiology.

The first fact relates to the preeminence, in skeletal acquisition and maintenance, of a signaling pathway consisting of the mammalian homologue of wingless in drosophila (Wnt), Lrp5 or Lrp 6, and β-catenin. This pathway's importance was firmly established through clinical observations from gain-of-function and loss-of-function mutations in the LRP5 . . . [Full Text of this Article]

Source Information

Dr. Rosen is a senior scientist at the Maine Medical Center Research Institute, Scarborough.

This article has been cited by other articles:

• Anderson, G. M., Cook, E. H. Jr., Blakely, R. D., de Jong, W. H.A., de Vries, E. G.E., Kema, I. P., Speth, R. C., Rosen, C. (2009). Serotonin Rising. NEJM 360: 2580-2582 [Full Text]